TIZIANA LIFE SCIENCES LTD

NASDAQ: TLSA (Tiziana Life Sciences Ltd)

最近更新时间: 昨天, 8:09AM

1.74

-0.03 (-1.69%)

前收盘价格 1.77
收盘价格 1.74
成交量 156,887
平均成交量 (3个月) 332,187
市值 206,753,776
股市价格/股市净资产 (P/B) 22.99
52周波幅
0.630 (-63%) — 2.60 (49%)
利润日期 23 Jun 2025 - 8 Jul 2025
稀释每股收益 (EPS TTM) -0.110
总债务/股东权益 (D/E MRQ) 2.69%
流动比率 (MRQ) 1.02
营业现金流 (OCF TTM) -1.53 M
杠杆自由现金流 (LFCF TTM) -8.99 M
资产报酬率 (ROA TTM) -84.13%
股东权益报酬率 (ROE TTM) -250.49%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 Tiziana Life Sciences Ltd 混合的 混合的

AIStockmoo 评分

-0.9
分析师共识 2.0
内部交易活动 NA
价格波动 -1.0
技术平均移动指标 -2.5
技术振荡指标 -2.0
平均 -0.88

相关股票

股票 市值 DY P/E(TTM) P/B
TLSA 207 M - - 22.99
MESO 2 B - - 3.70
TSHA 1 B - - 5.08
SANA 1 B - - 6.10
NTLA 1 B - - 1.32
ORIC 1 B - - 2.83

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 43.06%
机构持股比例 2.73%

所有权

姓名 日期 持有股份
Dauntless Investment Group, Llc 30 Sep 2025 2,735,933
Ewa, Llc 30 Sep 2025 46,050
日期 类型 细节
02 Dec 2025 公告 Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
02 Dec 2025 公告 Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
25 Nov 2025 公告 Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
25 Nov 2025 公告 Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
13 Nov 2025 公告 Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
13 Nov 2025 公告 Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
29 Oct 2025 公告 Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
29 Oct 2025 公告 Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
30 Sep 2025 公告 Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
30 Sep 2025 公告 Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
25 Sep 2025 公告 Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
25 Sep 2025 公告 Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
24 Sep 2025 公告 Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
24 Sep 2025 公告 Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
15 Sep 2025 公告 Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
15 Sep 2025 公告 Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
09 Sep 2025 公告 Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 公告 Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 公告 Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
09 Sep 2025 公告 Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票